1. CONFIDENTIAL 0 0 Paul Stoffels, M.D. Chief Scientific Officer Worldwide Chairman, Pharmaceuticals

2. CONFIDENTIAL 1 1 A Legacy of Innovation, Grounded in Science Inspired by the legacy of Dr. Paul Janssen in Global Health “Dr. Paul” was a leader in transformational drug development –Discovered 80 new medicines including four listed as essential medicines by the World Health Organization (WHO) A passion for addressing unmet needs for global public health

3. CONFIDENTIAL 2 2 Global Public Health Advancing global health and well-being requires: Focused, innovative approaches toward science and research & development and Sustainable access to medicines and care 1 2

4. CONFIDENTIAL 3 3 Focused R&D Innovations Global health challenges in resource-limited settings call for products designed to address specific needs Harness the best science in the world to develop and improve treatments for greatest unmet need including HIV, tuberculosis, and neglected tropical diseases

5. CONFIDENTIAL 4 4 Developing New Medicines for MDR-TB Bedaquiline: TB drug with a new mechanism of action granted accelerated approval by the U.S., EU, and Korea, for the treatment of pulmonary MDR-TB as part of combination therapy in adults WHO Interim Policy Guidance provides conditions for rational use in low and middle income countries Unprecedented update of the WHO guidelines within six months after FDA approval

6. CONFIDENTIAL 5 5 Innovating New Solutions for Series Health Challenges through Partnerships “…the first time in 40 years that the agency had approved a drug that attacked tuberculosis in a different way from the current treatments on the market.” F.D.A. Approves Drug for Resistant Tuberculosis

7. CONFIDENTIAL 6 6 Collaboration with Multiple Stakeholders is Key

8. CONFIDENTIAL 7 7 Our Global Access & Partnerships Program for HIV Portfolio of 3 HIV treatments: –PREZISTA ® (darunavir) –INTELENCE ® (etravirine) –EDURANT TM (rilpivirine) Focus is sustainable HIV drug access and appropriate use of our medicines in resource- limited countries –Sub-Saharan Africa (SSA) and least developed countries (LDCs) –Lower middle-income countries

9. CONFIDENTIAL 8 8 Creating Sustainable HIV and MDR-TB Drug Access in Resource-Limited Countries